Follow Us

header ads
header ads

Digital Therapeutics Market Value is Projected to Reach US$ 11.82 Bn in 2027

 

Precedence Research, Recently Published Report on “Digital Therapeutics Market Size, Share, Growth, Trends, Segment Forecasts, Regional Outlook 2020 - 2027”. The report offers an up-to-date analysis regarding the current market scenario, latest trends, key drivers, potential challenges, profitability graph and the overall market environment.

The global Digital Therapeutics Market value is projected to reach US Dollar 11.82 billion by 2027 and is projected to expand at a CAGR of ~20.3% from 2020 to 2027.

 



Digital therapeutics is a part of health, but all digital health solutions are not digital therapeutics solutions. Basic difference between digital therapeutics and digital health is completely based on the clinical outcomes for patients. For example, digital therapeutics does not comprise of consumer health-oriented technologies that include calorie-counters and step-counters. It’s a new class of healthcare products that uses digital technology to prevent, manage, or treat medical conditions. Additionally, it uses digital health technologies in treating psychological conditions of patients. Hence, the aforementioned factors positively influence the market growth for digital therapeutics.

Growth Factors

Increasing penetration of internet usage and smartphones particularly in the developing countries estimated as the key factor to propel the market growth. For instance, India ranked 47th and 36th in 2013 and 2015 by Google Inc. for smartphone penetration. In addition, rising need to curb the increasing spending on healthcare sector also anticipated to drive the market growth over the forecast timeframe.

Get the Sample Pages of Report for More Understanding@ https://www.precedenceresearch.com/sample/1128

Furthermore, rising prevalence of chronic diseases such as diabetes, obesity, smoking cessation, and many others across the globe is the other most prominent factor that impels the market growth. As per the statistics published by the International Diabetes Federation (IDF), in every 7 seconds a person dies from diabetes and its complications. In addition to this, the total number of people suffering from diabetes anticipated to rise by 48% from 424.9 Million in 2017 to 628.6 Million by 2045. Hence diabetes and similar other chronic disease are a major threat to the economy. To curb the rate of increasing chronic diseases along with rising awareness among the public related to health and fitness is likely to boost the growth of digital therapeutics in the upcoming years.

However, the undefined payment procedures along with lack of efficient monetization strategies projected to hamper the market growth. Nonetheless, integration of digital therapeutics platform with machine learning and artificial intelligence opens up new opportunity in the sector.

Report Highlights

  • North America emerged as a global leader in 2019 owing to increasing number of reforms pertaining to curtail the rising healthcare spending across the region
  • The Asia Pacific expected to witness the fastest growth over the analysis period because of large consumer base along with rising geriatric population in the region
  • Software segment captured the largest value share based on product type for the year 2019 and projected to register the fastest growth over the analysis timeframe
  • Based on application, diabetes dominated the global market in 2019 and estimated to forecast same trend over the upcoming period due to rising prevalence of diabetes across the globe
  • Obesity is the other major concerned disease that expected to exhibit the fastest growth over the forthcoming years owing to changing eating habits largely influenced by the western pattern

Buy This Premium Research Report@ https://www.precedenceresearch.com/checkout/1128

Regional Snapshots

North America captured the largest market share in the global digital therapeutics market and expected to retain its position over the upcoming years. The growth of the region is mainly attributed to the increasing focus towards a patient-centric healthcare approach coupled with need to curtail the increasing spending on healthcare sector. Further, rising cases of diabetes across the region along with its cost to the economy is the other major factor that influences the market growth for digital therapeutics in the region.

On the contrary, the Asia Pacific exhibits the fastest growth rate during the forthcoming years. The significant growth of the region is mainly due to rapid urbanization and fast changing technology landscape in the region. Further, rising geriatric population in the region further impels the application developers to bring advancement and patient centric apps in the region.

Key Players & Strategies

The global digital therapeutics industry is at its niche stage; however, experiences significant merger, partnership, and new product launch & development. For instance, in September 2019, TrialCard, a company that works in conjunction with pharma manufacturers to connect patients to services and medications, announced to acquire Mango Health. The acquisition helped TrialCard to offer best engagement and adherence solution to their patients. Similarly, in July 2020, Biocon Biologics India, a biosimilars company, and Voluntis, a digital therapeutics company, announced to enter into a collaboration agreement. Under this agreement, Biocon in collaboration with Voluntis develops and distributes innovative digital therapeutic solutions for type-2 diabetes patients.

Some of the key players operating in the market are Fitbit Health Solutions, 2MORROW, Inc., Medtronic Plc., Livongo Health, Inc., Pear Therapeutics, Inc., Omada Health, Inc., Resmed, Inc. (Propeller Health), Proteus Digital Health, Inc., Welldoc, Inc., Voluntis, Inc., Canary Health Inc., Noom, Inc., Mango Health Inc., and Dthera Sciences among others.

Market Segmentation

By Product

  • Device
  • Software

By Sales Channel

  • Business-to-Consumer (B2C)
  • Business-to-Business (B2B)

By Application

  • Obesity
  • Diabetes
  • Central Nervous System (CNS) Disease
  • Gastrointestinal Disorder (GID)
  • Cardiovascular Disease (CVD)
  • Smoking Cessation
  • Respiratory Disease
  • Others

By Regional Outlook

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World
TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective
1.2. Scope of the Study
1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach
2.2. DataSources
2.3. Assumptions& Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Digital Therapeutics Market Variables and Scope

4.1. Introduction
4.2. Market Classification and Scope
4.3. Market SWOT Analysis

Chapter 5. COVID 19 Impact on Digital Therapeutics Market

5.1. Covid-19: Digital Therapeutics Industry Impact
5.2. Digital Therapeutics Business Impact Assessment: Covid-19
5.2.1. Distribution Channel Challenges/Disruption
5.2.2. Market Trends and Digital Therapeutics Opportunities in the COVID-19 Landscape
5.3. Strategic Measures against Covid-19
5.3.1. Government Support and Initiative to Combat Covid-19
5.3.2. Proposal for Digital Therapeutics Manufacturers to deal with Covid-19 Pandemic Scenario

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics
6.1.1. Market Drivers
6.1.1.1. Increasing Penetration of Digital Healthcare Applications & Platforms
6.1.1.2. Rapid Adoption of Smartphones & Tablets
6.1.2. Market Restraints
6.1.2.1. Lack of Proper Monetization Strategy
6.1.3. Market Opportunities
6.1.3.1. Implementation of Machine Learning and Artificial Intelligence in Digital Therapeutics Platforms

Chapter 7. Global Digital Therapeutics Market: Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis
7.1.1.1. Digital Therapeutics Market Revenue by Manufacturer (2015-2020)
7.1.1.2. Digital Therapeutics Market Revenue Market Share by Manufacturer (2015-2020)
7.1.2. Key Organic/Inorganic Strategies Adopted by Players
7.1.2.1. Product Portfolio Expansion, Capacity Expansion, Product Innovation
7.1.2.2. Merger and Acquisition, Collaboration and Partnerships
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers

Chapter 8. Global Digital Therapeutics Market, By Product Type

8.1. Digital Therapeutics Market, by Product Type, 2016-2027
8.1.1. Device
8.1.1.1. Market Revenue and Forecast (2016-2027)
8.1.2. Software
8.1.2.1. Market Revenue and Forecast (2016-2027)

Chapter 9. Global Digital Therapeutics Market, By Sales Channel

9.1. Digital Therapeutics Market, by Sales Channel, 2016-2027
9.1.1. Business-to-Consumer (B2C)
9.1.1.1. Market Revenue and Forecast (2016-2027)
9.1.1.2. Caregiver
9.1.1.3. Patient
9.1.2. Business-to-Business (B2B)
9.1.2.1. Market Revenue and Forecast (2016-2027)
9.1.2.2. Healthcare Provider
9.1.2.3. Employer
9.1.2.4. Others

Chapter 10. Global Digital Therapeutics Market, By Application

10.1. Digital Therapeutics Market, by Application, 2016-2027
10.1.1. Obesity
10.1.1.1. Market Revenue and Forecast (2016-2027)
10.1.2. Diabetes
10.1.2.1. Market Revenue and Forecast (2016-2027)
10.1.3. Central Nervous System (CNS) Disease
10.1.3.1. Market Revenue and Forecast (2016-2027)
10.1.4. Gastrointestinal Disorder (GID)
10.1.4.1. Market Revenue and Forecast (2016-2027)
10.1.5. Cardiovascular Disease (CVD)
10.1.5.1. Market Revenue and Forecast (2016-2027)
10.1.6. Smoking Cessation
10.1.6.1. Market Revenue and Forecast (2016-2027)
10.1.7. Respiratory Disease
10.1.7.1. Market Revenue and Forecast (2016-2027)
10.1.8. Others
10.1.8.1. Market Revenue and Forecast (2016-2027)

Chapter 11. Global Digital Therapeutics Market, Regional Estimates and Trend Forecast

11.1. North America
11.1.1. Market Revenue Forecast by Product Type (2016-2027)
11.1.2. Market Revenue Forecast by Sales Channel (2016-2027)
11.1.3. Market Revenue Forecast by Application (2016-2027)
11.1.4. U.S
11.1.4.1. Market Revenue Forecast (2016-2027)
11.1.5. Canada
11.1.5.1. Market Revenue Forecast (2016-2027)
11.2. Europe
11.2.1. Market Revenue Forecast by Product Type (2016-2027)
11.2.2. Market Revenue Forecast by Sales Channel (2016-2027)
11.2.3. Market Revenue Forecast by Application (2016-2027)
11.2.4. UK
11.2.4.1. Market Revenue Forecast (2016-2027)
11.2.5. Germany
11.2.5.1. Market Revenue Forecast (2016-2027)
11.2.6. France
11.2.6.1. Market Revenue Forecast (2016-2027)
11.2.7. Rest of EU
11.2.7.1. Market Revenue Forecast (2016-2027)
11.3. Asia Pacific (APAC)
11.3.1. Market Revenue Forecast by Product Type (2016-2027)
11.3.2. Market Revenue Forecast by Sales Channel (2016-2027)
11.3.3. Market Revenue Forecast by Application (2016-2027)
11.3.4. China
11.3.4.1. Market Revenue Forecast (2016-2027)
11.3.5. India
11.3.5.1. Market Revenue Forecast (2016-2027)
11.3.6. Japan
11.3.6.1. Market Revenue Forecast (2016-2027)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue Forecast (2016-2027)
11.4. LATAM
11.4.1. Market Revenue Forecast by Product Type (2016-2027)
11.4.2. Market Revenue Forecast by Sales Channel (2016-2027)
11.4.3. Market Revenue Forecast by Application (2016-2027)
11.4.4. Brazil
11.4.4.1. Market Revenue Forecast (2016-2027)
11.4.5. Rest of LATAM
11.4.5.1. Market Revenue Forecast (2016-2027)
11.5. Middle East and Africa (MEA)
11.5.1. Market Revenue Forecast by Product Type (2016-2027)
11.5.2. Market Revenue Forecast by Sales Channel (2016-2027)
11.5.3. Market Revenue Forecast by Application (2016-2027)
11.5.4. GCC
11.5.4.1. Market Revenue Forecast (2016-2027)
11.5.5. North Africa
11.5.5.1. Market Revenue Forecast (2016-2027)
11.5.6. South Africa
11.5.6.1. Market Revenue Forecast (2016-2027)
11.5.7. Rest of MEA
11.5.7.1. Market Revenue Forecast (2016-2027)

Chapter 12. Company Profiles

12.1. Fitbit Health Solutions
12.1.1. Company Overview, Business Information, Manufacturing Area
12.1.2. Product Portfolio Analysis
12.1.2.1. Product Details, Specification, Application
12.1.3. Revenue, Price and Gross Margin (2015-2020)
12.1.4. Recent Developments and Strategies
12.2. 2MORROW, Inc.
12.2.1. Company Overview, Business Information, Manufacturing Area
12.2.2. Product Portfolio Analysis
12.2.2.1. Product Details, Specification, Application
12.2.3. Revenue, Price and Gross Margin (2015-2020)
12.2.4. Recent Developments and Strategies
12.3. Medtronic Plc.
12.3.1. Company Overview, Business Information, Manufacturing Area
12.3.2. Product Portfolio Analysis
12.3.2.1. Product Details, Specification, Application
12.3.3. Revenue, Price and Gross Margin (2015-2020)
12.3.4. Recent Developments and Strategies
12.4. Livongo Health, Inc.
12.4.1. Company Overview, Business Information, Manufacturing Area
12.4.2. Product Portfolio Analysis
12.4.2.1. Product Details, Specification, Application
12.4.3. Revenue, Price and Gross Margin (2015-2020)
12.4.4. Recent Developments and Strategies
12.5. Pear Therapeutics, Inc.
12.5.1. Company Overview, Business Information, Manufacturing Area
12.5.2. Product Portfolio Analysis
12.5.2.1. Product Details, Specification, Application
12.5.3. Revenue, Price and Gross Margin (2015-2020)
12.5.4. Recent Developments and Strategies
12.6. Omada Health, Inc.
12.6.1. Company Overview, Business Information, Manufacturing Area
12.6.2. Product Portfolio Analysis
12.6.2.1. Product Details, Specification, Application
12.6.3. Revenue, Price and Gross Margin (2015-2020)
12.6.4. Recent Developments and Strategies
12.7. Resmed, Inc. (Propeller Health)
12.7.1. Company Overview, Business Information, Manufacturing Area
12.7.2. Product Portfolio Analysis
12.7.2.1. Product Details, Specification, Application
12.7.3. Revenue, Price and Gross Margin (2015-2020)
12.7.4. Recent Developments and Strategies
12.8. Proteus Digital Health, Inc.
12.8.1. Company Overview, Business Information, Manufacturing Area
12.8.2. Product Portfolio Analysis
12.8.2.1. Product Details, Specification, Application
12.8.3. Revenue, Price and Gross Margin (2015-2020)
12.8.4. Recent Developments and Strategies
12.9. Welldoc, Inc.
12.9.1. Company Overview, Business Information, Manufacturing Area
12.9.2. Product Portfolio Analysis
12.9.2.1. Product Details, Specification, Application
12.9.3. Revenue, Price and Gross Margin (2015-2020)
12.9.4. Recent Developments and Strategies
12.10. Voluntis, Inc.
12.10.1. Company Overview, Business Information, Manufacturing Area
12.10.2. Product Portfolio Analysis
12.10.2.1. Product Details, Specification, Application
12.10.3. Revenue, Price and Gross Margin (2015-2020)
12.10.4. Recent Developments and Strategies

Chapter 13. Appendix

13.1. About Us
13.2. Glossary of Terms

Buy this Premium Research Report@ https://www.precedenceresearch.com/checkout/1128

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 774 402 6168

Contact Us:

Precedence Research

Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call: +1 774 402 6168

Email: sales@precedenceresearch.com

Blog: https://precedenceresearchnews.wordpress.com

Follow us on LinkedIn| Twitter| Facebook

Post a Comment

0 Comments